VEGF Overexpression Is a Valuable Prognostic Factor for Non-Hodgkin’s Lymphoma Evidence from a Systemic Meta-Analysis

Table 3

VEGF overexpression and clinicopathological features of NHL.

Clinicopathological features	Number of studies	Number of patients	Analytical model	Pooled OR (95% CI)	value	Heterogeneity
						(%)	value
Performance status (ECOG); (0-1 versus ⩾ 2)	4	502	REM	0.84 (0.39–1.88)	0.64	67.8	0.025
LDH level; (normal versus elevated)	4	502	FEM	0.98 (0.64–1.51)	0.93	5	0.37
IPI score; (0–2 versus 3–5)	4	383	REM	0.45 (0.15–1.39)	0.17	78.3	0.003
Tumor staging; (I II versus III IV)	5	483	REM	0.76 (0.36–1.57)	0.45	62.4	0.03
B symptom; (absent versus present)	5	547	FEM	0.96 (0.65–1.42)	0.84	0	0.61
Relapse; (no versus yes)	3	253	FEM	0.74 (0.36–1.5)	0.4	0	0.72